Genelux Investor Presentation Deck

Estimated Billion Dollar Plus annual Olvi-Vec Commercial Opportunity (US) Ovarian Cancer Non-Small Cell Lung Cancer GENELUX Additional revenue drivers: Re-treatment ➤ Front-Line therapy ➤ Additional Indications, i.e.: Small Cell Lung Cancer Pancreatic Cancer 1. Polaris Market Research 2. NIH Ovarian Cancer Fact Sheet =100,000 patients Ovarian Cancer Market¹ ~$1.8B in 2022, expected CAGR growth ~23.5% iii 70-80% will relapse ~236,511 women in the US currently 2 Drivers of Market Penetration The Phase 3 population is a broad category of patients with significant unmet medical need, including those excluded from other therapies or trials. 24

View entire presentation